Canagliflozin vs SS-31 (Elamipretide)
A side-by-side research comparison of Canagliflozin and SS-31 (Elamipretide) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Canagliflozin | SS-31 (Elamipretide) |
|---|---|---|
| Full name | Canagliflozin (SGLT2 Inhibitor) | SS-31 / Elamipretide (Bendavia) |
| Category | Anti-Aging | Anti-Aging |
| Status | FDA-approved drug | Investigational |
| Mechanism | Blocks the sodium-glucose cotransporter 2 in the kidney, causing excess glucose to be excreted in urine. This lowers blood glucose independent of insulin, reduces blood pressure and weight, and produces cardio-renal protective effects. | Targets cardiolipin in inner mitochondrial membrane, stabilizes cytochrome c binding, optimizes electron transfer efficiency, and reduces mitochondrial ROS by 50%. |
| Molecular weight | 444.52 Da | 640.8 Da |
| Half-life | ~11-13 hours | 4-6 hours |
| Bioavailability | ~65% oral | High (SubQ) |
| Typical dose | 100-300 mg per day | 5-40 mg |
| Frequency | Once daily | Daily |
| Route | Oral tablet | Subcutaneous or IV |
Canagliflozin reported benefits
- Insulin-independent glucose lowering
- Cardiovascular protection
- Kidney protection
- Blood pressure reduction
- Weight loss
- Longevity signal (ITP data)
SS-31 (Elamipretide) reported benefits
- Mitochondrial function optimization
- Reduced oxidative stress
- Cardioprotection
- Improved exercise capacity
- Renal protection
- Cellular energy
Related comparisons
Research and educational reference only. Not medical advice.